发明名称 |
Anti-cancer tamoxifen-melatonin hybrid ligand |
摘要 |
A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxytamoxifen and also melatonin, with the tamoxifen or 4-hydroxytamoxifen and melatonin's being linked by an unsubstituted C2-C6 alkyl linker between the tamoxifen amine and the carbonyl of melatonin. |
申请公布号 |
US8785501(B2) |
申请公布日期 |
2014.07.22 |
申请号 |
US201013497954 |
申请日期 |
2010.10.12 |
申请人 |
Duquesne University of the Holy Spirit |
发明人 |
Witt-Enderby Paula A.;Davis Vicki L.;Lapinsky David |
分类号 |
A01N33/02;A61K31/135;A01N43/38;A61K31/405 |
主分类号 |
A01N33/02 |
代理机构 |
|
代理人 |
Johnson, Esq. Barbara E. |
主权项 |
1. A pharmaceutically active agent consisting essentially of a hybrid ligand of tamoxifen and melatonin linked by a 2-6 carbon alkyl linker conjoining said tamoxifen and said melatonin via a covalent linkage between an amino moiety of said tamoxifen and a hydroxylamino moiety of said melatonin. |
地址 |
Pittsburgh PA US |